brd9

dBRD9 HCl is a PROTAC composed of the BRD9 inhibitor BI 7273 conjugated to the cereblon E3 ligase ligand pomalidomide . dBRD9 HCl is a potent and selective degrader of BRD9 (IC50 = 56.6 nM in MOLM-13 cells). dBRD9 HCl does not degrade BRD4 or BRD7 at concentrations up to 5 μM. dBRD9 HCl displays antiproliferative effects in human AML cell lines.

BRD9 ligand-6 serves as a ligand for the target protein in PROTAC applications. It is utilized in the synthesis of FHD-609.

PROTAC BRD9 Degrader-2 is a bifunctional compound engineered for the targeted degradation of BRD9 (Bromodomain containing 9) in cancer research applications.

BRD9 Degrader-3 (compound B20) is a molecular glue for BRD9 with a DC50 of less than 1.25 nM.

PROTAC BRD9 Degrader-7 is a selective and orally active BRD9 degrader with a DC50 of 1.02 nM and demonstrates superior pharmacokinetics, evidenced by a Cmax of 3436.95 ng mL [1].

PROTAC BRD9 Degrader-5 is a proteolysis targeting chimera (PROTAC) designed to specifically degrade Bromodomain-containing protein 9 (BRD9).

PROTAC BRD9 Degrader-4 is a bifunctional degrader that targets BRD9, specifically designed for applications in cancer research.

PROTAC BRD9-binding moiety 1 hydrochloride inhibits BRD9 activity by binding to BRD9, utilizing the PROTAC (Proteolysis Targeting Chimera) mechanism.

PROTAC BRD9-binding moiety 5, a selective binder of BRD9 with an IC50 value of 4.20 μM, is utilized in PROTAC synthesis and exhibits antiproliferative activity against cancer cells [1].

BRD9 ligand-7 acts as the target protein ligand for PROTAC (Ligand for Target Protein for PROTAC) and is utilized in the synthesis of BRD9 Degrader-1.

PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

BRD9 Ligand-5 (Compound 172-11) serves as a ligand for the target protein in PROTAC applications. It is utilized in the synthesis of CFT8634.

PROTAC BRD9 Degrader-3 is a bifunctional degrader targeting BRD9, used in cancer research.

PROTAC BRD9 Degrader-6, with an IC50 value of 0.13 nM, is a potent degrader of BRD9 suitable for research on BAF complex-related disorders [1].

PROTAC BRD9 Degrader-1 is a leading PROTAC BRD9 chemical degrader with an IC50 of 13.5 nM.

BRD9 Degrader-4 (BRD9c) is a bifunctional molecule that acts as an effective BRD9 degrader with a DC50 value of ≤25 nM. It exhibits anticancer properties.

dBRD9 is a PROTAC. dBRD9 is a double-acting molecule, partially containing Bromodomain-containing protein 9 (BRD9), ligand that recruits the cereblon E3 ubiquitin ligase. Ligand that recruits the cereblon E3 ubiquitin ligase. dBRD9 can inhibit the degradation of BRD9 in MOLM-13 cells, and the IC50 is 104 nM.

BRD7-IN-1 free base, a modified derivative of BI7273 (BRD7 9 inhibitor), interacts with a VHL ligand via a linker to form the PROTAC VZ185 (targeting BRD7 9 with DC50 values of 4.5 and 1.8 nM, respectively)[1].

Thalidomide-NH-PEG2-C2-NH-Boc, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon-targeting Thalidomide ligand with a PEG linker for the synthesis of dBRD9 (compound 6). This selective BRD9 probe PROTAC degrader is utilized in researching BAF complex biology.

VZ185 is an effective and selective dual BRD7 9 PROTAC degrader (DC50s: 4.5 and 1.8 nM, respectively).

EA-89 is an effective and selective inhibitor of BRD9, exhibiting antitumor activity. It serves as a target protein ligand for PROTAC and can be utilized in the synthesis of PROTACQA-68.

CW-3308 is an orally active PROTAC that targets BRD9. It is composed of the PROTAC target protein ligand Naphthyridin-Me-dimethoxybenzene-COOH, the linker 3-Azaspiro[5.5]undecane-9-methanol, and the E3 ubiquitin ligase ligand Thalidomide-methylpyrrolidine. The coupling of the E3 ubiquitin ligase ligand with the linker results in the conjugate Thalidomide-pyrrolidine-C-azaspiro.

DCAF1 Binder 2, an E3 ligase ligand, is implicated in BRD9, kinase, and selective Bruton's tyrosine kinase (BTK) degradation.

BRD7-IN-1, a modified derivative of BI7273 (BRD7 9 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD7 9 with DC50 values of 4.5 and 1.8 nM, respectively [1].